Abaloparatide

In plain language

Abaloparatide is a once-daily injection for osteoporosis in women after menopause at high risk of fracture, sold as Tymlos. It builds new bone rather than just slowing bone loss.

It is a shortened copy of parathyroid hormone-related protein (PTHrP), the hormone some cancers overproduce, with a few amino-acid changes. Like teriparatide (a copy of parathyroid hormone), it works by briefly stimulating bone-building cells, but it is designed to tilt the response toward formation rather than breakdown.

For students

Abaloparatide is a 34-residue analogue of human PTHrP(1-34) (about 3,960 Da) with substitutions at positions 1, 3, 4, 18, 22 and 23 that bias signaling at the PTH/PTHrP receptor (PTHR1) toward the G-protein coupled (Gs/cAMP) bone-anabolic response and away from beta-arrestin-mediated desensitization, a hypothesis advanced by Thomas Gardella's group.

The ACTIVE trial (n=2,463 postmenopausal women) showed vertebral fracture risk reduction of 86% and nonvertebral fracture reduction of 43% versus placebo over 18 months, numerically greater than the open-label teriparatide arm's 80% vertebral reduction. Treatment is capped at 2 years total (including teriparatide) because of a rat osteosarcoma boxed warning, a class effect of sustained high-dose PTH receptor agonism, though the risk has not materialized as a clinical signal in the decades of teriparatide use.

For researchers and instructors

Biochemistry. PTHR1 signal bias (cAMP versus beta-arrestin recruitment) is one of the first approved-drug examples of biased agonism at a class B GPCR, and the central mechanistic teaching point.

Pharmacology. 80 mcg daily subcutaneous injection; capped at 2 years by label; hypercalciuria and orthostatic hypotension (initial doses given sitting); boxed warning for osteosarcoma risk is a class effect.

Human evidence. ACTIVE (n=2,463) for efficacy versus placebo and open-label teriparatide; the follow-on VAX-D extension and real-world data support bone density gains after discontinuation, and the anabolic-to-antiresorptive sequencing literature applies.

Teaching point. Teaches biased agonism as an actionable drug-design principle, and how class-effect warnings (rat osteosarcoma) persist beyond their evidentiary basis.